Biogen announces plans to start their global phase 3 trial of Omaveloxolone in children aged 2-15, with sites in the UK

Biogen have shared their plan to initiate their BRAVE study, a global phase 3 trial of Omaveloxolone (SKYCLARYS®) in children aged 2-15 years. The trial will study the effects and long-term safety of the drug in this population. 

The London Ataxia Centre, Sheffield Ataxia Centre and Oxford Ataxia Centre are UK sites for this trial. Individuals interested in taking part should speak to their healthcare provider. The trial is now recruiting participants in the UK.

Sheffield Ataxia Centre contact: ​Dr Santosh Mordekar, santosh.mordekar@nhs.net ​

​London Ataxia Centre contact:​ Dr Shpresa Pula, shpresa.pula1@nhs.net 

Oxford Ataxia Centre contact: Prof Andrea Nemeth, andrea.nemeth@ndcn.ox.ac.uk. 

Read Biogen’s letter to FA community here.

Read more about the trial here.

Read more about Omaveloxolone here.